Table 2.

Anti-tumor efficacy of each different ADS-I treatment in C6 glioma-bearing rats (n = 8)

Groups	Dose (mg)	MST (days)	Median (days)	ILS over blank wafer (%)	ILS over ADS-I solution (%)
Blank wafer	\	14.70 ± 2.386	15	\	\
ADS-I wafer	0.77	31.50 ± 2.830	25	114.29	23.53
ADS-I wafer	1.53	41.57 ± 3.423	45	182.79	63.02
ADS-I solution	1.53	25.50 ± 3.865	22	73.47	\

MST: mean survival time, ILS: increase in life span [(T/C-1) ×100%], where T and C stand for the treatment and control groups respectively.